A Phase I Dose Finding Study of MB-CART2219.1
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age12-75
SponsorUniversity Hospital Tuebingen
About this trial
A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignancies
Eligibility criteria
Qualifiers
For Cohort I Lymphoma, adults: Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).
For Cohort II ALL, pediatrics: Subject is ≥ 12 years of age at the time of signing ICF.
Patient or legal guardian understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.
Able to adhere to the study visit schedule and other protocol requirements as well as agrees to continued follow up for up to 15 years as mandated by the regulatory guidelines for gene therapy trials.
Disqualifiers
Any investigational agent
Immunsupressive medication
Plasmapheresis
Major surgery (as defined by the investigator)
Trial design
Treatments tested in this trial
- CAR-T cells targeting CD19 and CD22
Treatment groups
36 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov